EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review

Xando Díaz-Villamarín iD, María Teresa Nieto-Sánchez iD, María Martínez-Pérez, Paula Novo-González, Emilio Fernández-Varón iD, Alicia Torres-García iD, Beatriz González Astorga iD, Isabel Blancas iD, José Cabeza-Barrera iD, Rocío Morón iD

Pharmaceutics · 22.04.2025 · 17 (5) · 542

DOI: 10.3390/pharmaceutics17050542 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 22.04.2025. Verfasst von Xando Díaz-Villamarín und 9 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigación Biosanitaria de Granada (Ibs. Granada), 18012 Granada, Spain. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Irinotecan is used in monotherapy or combined with other drugs for treating different cancer streams. SN-38, the active metabolite of irinotecan, is 70% inactivated by the uridine diphosphate (UDP) glucuronosyltransferase family 1 member A1 (UGT1A1) enzyme. The UGT1A1*6 (rs4148323) and *28 (rs3064744) alleles in the gene encoding the enzyme lead to decreased enzyme expression and increased severe irinotecan toxicity. Carrying one or two copies of these alleles results in a UGT1A1 intermediate or poor metabolizer status (IM, PM). The Food and Drug Administration (FDA)-approved drug labels and European Medicines Agency (EMA) European Public Assessment Report (EPAR) for irinotecan recommend dose adjustments based on UGT1A1 genotypes, but only for UGT1A1 PM patients. However, available pharmacogenetic (PGx) dosing guidelines for the UGT1A1–irinotecan interaction lack a consensus about considered genetic variants, genotype-translated phenotypes, and therapeutic recommendations. We aimed to describe evidence regarding the impact of the UGT1A1 genotype in irinotecan toxicity to inform irinotecan-dosing recommendations based on possible UGT1A1 genotypes.

Methods

A systematic review was performed to find all the Phase I clinical trials looking for the maximum tolerated dose (MTD) or dose-limiting toxicities (DLTs) of irinotecan depending on the UGT1A1 genotype.

Results

Toxicity-related events and the MTD of irinotecan differ among UGT1A1 normal metabolizers (NM), IM, and PM patients considering the UGT1A1*28 and/or *6 variants.

Conclusions

Dose adjustments might also be recommended for UGT1A1 IM patients (*1/*28 or *1/*6 genotypes), with a 15% dose reduction considered.

Schlagwörter

Stichwörter der Autor:innen

UGT1A1clinical pharmacyirinotecanmaximum tolerated dosepersonalized medicinepharmacogeneticspharmacogenomic

Autor:innen und Institutionen

  • Instituto de Investigación Biosanitaria de Granada (Ibs. Granada), 18012 Granada, Spain.
  • Hospital Pharmacy, Hospital Universitario San Cecilio, 18016 Granada, Spain.
  • Hospital Pharmacy, Hospital Regional Severo Ochoa, 28914 Leganés, Spain.
  • Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, 18016 Granada, Spain.
  • Medical Oncology, Hospital Universitario San Cecilio, 18016 Granada, Spain.

ORCID-Profile: Xando Díaz-Villamarín, María Teresa Nieto-Sánchez, Emilio Fernández-Varón, Alicia Torres-García, Beatriz González Astorga, Isabel Blancas, José Cabeza-Barrera, Rocío Morón

Zitieren

APA

Díaz-Villamarín, X., Nieto-Sánchez, M. T., Martínez-Pérez, M., Novo-González, P., Fernández-Varón, E., Torres-García, A., González Astorga, B., Blancas, I., Cabeza-Barrera, J., & Morón, R. (2025). Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review. Pharmaceutics, 17(5), 542. https://doi.org/10.3390/pharmaceutics17050542

Vancouver

Díaz-Villamarín X, Nieto-Sánchez MT, Martínez-Pérez M, Novo-González P, Fernández-Varón E, Torres-García A, et al. Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review. Pharmaceutics. 2025;17(5):542. doi:10.3390/pharmaceutics17050542

BibTeX
@article{DazVillamarn2025,
  author = {Díaz-Villamarín, Xando and Nieto-Sánchez, María Teresa and Martínez-Pérez, María and Novo-González, Paula and Fernández-Varón, Emilio and Torres-García, Alicia and González Astorga, Beatriz and Blancas, Isabel and Cabeza-Barrera, José and Morón, Rocío},
  title = {Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {5},
  pages = {542},
  doi = {10.3390/pharmaceutics17050542}
}
Kostenlos starten →